These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 9139802)

  • 1. Estrogen receptor residues required for stereospecific ligand recognition and activation.
    Bocchinfuso WP; Korach KS
    Mol Endocrinol; 1997 May; 11(5):587-94. PubMed ID: 9139802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational analysis of the estrogen receptor ligand-binding domain: influence of ligand structure and stereochemistry on transactivation.
    Kohno H; Bocchinfuso WP; Gandini O; Curtis SW; Korach KS
    J Mol Endocrinol; 1996 Jun; 16(3):277-85. PubMed ID: 8782086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen receptor stereochemistry: ligand binding orientation and influence on biological activity.
    Chae K; Gibson MK; Korach KS
    Mol Pharmacol; 1991 Nov; 40(5):806-11. PubMed ID: 1944245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diethylstilbestrol metabolites and analogs. Stereochemical probes for the estrogen receptor binding site.
    Korach KS; Chae K; Levy LA; Duax WL; Sarver PJ
    J Biol Chem; 1989 Apr; 264(10):5642-7. PubMed ID: 2925625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen receptor stereochemistry: receptor binding and hormonal responses.
    Korach KS; Levy LA; Sarver PJ
    J Steroid Biochem; 1987; 27(1-3):281-90. PubMed ID: 3695485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Function of N-terminal transactivation domain of the estrogen receptor requires a potential alpha-helical structure and is negatively regulated by the A domain.
    Métivier R; Petit FG; Valotaire Y; Pakdel F
    Mol Endocrinol; 2000 Nov; 14(11):1849-71. PubMed ID: 11075817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diethylstilbestrol metabolites and analogs: differential ligand effects on estrogen receptor interactions with nuclear matrix sites.
    Metzger DA; Curtis S; Korach KS
    Endocrinology; 1991 Apr; 128(4):1785-91. PubMed ID: 2004602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular determinants of the stereoselectivity of agonist activity of estrogen receptors (ER) alpha and beta.
    Mueller SO; Hall JM; Swope DL; Pedersen LC; Korach KS
    J Biol Chem; 2003 Apr; 278(14):12255-62. PubMed ID: 12547836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction.
    Carlson KE; Choi I; Gee A; Katzenellenbogen BS; Katzenellenbogen JA
    Biochemistry; 1997 Dec; 36(48):14897-905. PubMed ID: 9398213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-dimensional quantitative structure-activity relationship study of nonsteroidal estrogen receptor ligands using the comparative molecular field analysis/cross-validated r2-guided region selection approach.
    Sadler BR; Cho SJ; Ishaq KS; Chae K; Korach KS
    J Med Chem; 1998 Jun; 41(13):2261-7. PubMed ID: 9632359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of charged residues in an N-terminal portion of the hormone-binding domain of the human estrogen receptor important in transcriptional activity of the receptor.
    Pakdel F; Reese JC; Katzenellenbogen BS
    Mol Endocrinol; 1993 Nov; 7(11):1408-17. PubMed ID: 8114756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanistic aspects of estrogen receptor activation probed with constitutively active estrogen receptors: correlations with DNA and coregulator interactions and receptor conformational changes.
    Lazennec G; Ediger TR; Petz LN; Nardulli AM; Katzenellenbogen BS
    Mol Endocrinol; 1997 Aug; 11(9):1375-86. PubMed ID: 9259327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen receptor stereochemistry: ligand binding and hormonal responsiveness.
    Korach KS; Chae K; Gibson M; Curtis S
    Steroids; 1991 May; 56(5):263-70. PubMed ID: 1877066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two transcription activation functions in the amino terminus of the mouse estrogen receptor that are affected by the carboxy terminus.
    Gandini O; Kohno H; Curtis S; Korach KS
    Steroids; 1997 Jul; 62(7):508-15. PubMed ID: 9253789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reciprocal mutagenesis between human alpha(L349, M528) and rainbow trout (M317, I496) estrogen receptor residues demonstrates their importance in ligand binding and gene expression at different temperatures.
    Matthews JB; Clemons JH; Zacharewski TR
    Mol Cell Endocrinol; 2001 Oct; 183(1-2):127-39. PubMed ID: 11604233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FLP recombinase/estrogen receptor fusion proteins require the receptor D domain for responsiveness to antagonists, but not agonists.
    Nichols M; Rientjes JM; Logie C; Stewart AF
    Mol Endocrinol; 1997 Jun; 11(7):950-61. PubMed ID: 9178754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The inhibitory activity of a transdominant c-jun mutant fused to the ligand binding domain of the estrogen receptor.
    Kim S; Brown PH; Birrer MJ
    Oncogene; 1996 Mar; 12(5):1043-53. PubMed ID: 8649795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.
    MacGregor Schafer J; Liu H; Bentrem DJ; Zapf JW; Jordan VC
    Cancer Res; 2000 Sep; 60(18):5097-105. PubMed ID: 11016635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of aspartate 351 in transactivation and active conformation of estrogen receptor alpha.
    Kim JH; Lee MH; Kim BJ; Kim JH; Han SJ; Kim HY; Stallcup MR
    J Mol Endocrinol; 2005 Dec; 35(3):449-64. PubMed ID: 16326832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-Arylindenes and 2-arylindenones: molecular structures and considerations in the binding orientation of unsymmetrical nonsteroidal ligands to the estrogen receptor.
    Anstead GM; Wilson SR; Katzenellenbogen JA
    J Med Chem; 1989 Sep; 32(9):2163-71. PubMed ID: 2769689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.